Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer

Cancer

Volumn 117, Issue 17, 2011, Pages 3889-3899

  Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

angiogenesis; antiangiogenic therapy; biomarker; fibroblast growth factor; NSCLC; platelet derived growth factor; vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CADHERIN; CARBOPLATIN; COLLAGEN TYPE 18; CYCLOOXYGENASE 2; DOCETAXEL; FIBROBLAST GROWTH FACTOR; GEFITINIB; GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 8; MICRORNA; PACLITAXEL; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SURGERY; LYMPH NODE METASTASIS; MICROVASCULATURE; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051925916     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25935     Document Type: Review

References (100)

1. American Cancer Society. Cancer Facts & Figures, 2009. Atlanta, GA: American Cancer Society; 2009.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. V. 2.2010. Accessed Apr. 8, 2010.
3. Avastin,. Avastin (bevacizumab) [package insert]. South San Francisco, CA: Genentech; July 2009.
4. Carmeliet P, Jain RK,. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249-257.
5. Folkman J, Klagsbrun M,. Vascular physiology. A family of angiogenic peptides. Nature. 1987; 329: 671-672.
6. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009; 6: 327-338.
7. Jain L, Vargo CA, Danesi R, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009; 8: 2496-2508.
8. Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, Bremnes RM,. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol. 2008; 3: 963-970.
9. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG,. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008; 44: 946-953.
10. Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2002; 87: 694-701. (Pubitemid 35178743)
11. Kreuter M, Kropff M, Fischaleck A, et al. Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J. 2009; 33: 1383-1388.
12. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol. 2005; 18: 143-152. (Pubitemid 40128107)
13. Pathak AP, Hochfeld WE, Goodman SL, Pepper MS,. Circulating and imaging markers for angiogenesis. Angiogenesis. 2008; 11: 321-335.
14. Renyi-Vamos F, Tovari J, Fillinger J, et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res. 2005; 11: 7344-7353. (Pubitemid 41507693)
15. Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004; 57: 591-597. (Pubitemid 38725758)
16. Kadota K, Huang CL, Liu D, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008; 44: 1057-1067.
17. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001; 8: 72-79. (Pubitemid 32126827)
18. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 2000; 82: 1427-1432. (Pubitemid 30175909)
19. Trivella M, Pezzella F, Pastorino U, Harris AL, Altman DG,. Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol. 2007; 8: 488-499. (Pubitemid 46805904)
20. Ng QS, Goh V,. Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography. J Thorac Imaging. 2010; 25: 142-150.
21. de Langen AJ, Lubberink M, Boellaard R, et al. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med. 2008; 49: 1763-1768.
22. Folkman J, Shing Y,. Angiogenesis. J Biol Chem. 1992; 267: 10931-10934.
23. Lohela M, Bry M, Tammela T, Alitalo K,. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009; 21: 154-165.
24. Nakashima T, Huang CL, Liu D, et al. Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit. 2004; 10: BR157-BR165. (Pubitemid 38878774)
25. Bremnes RM, Camps C, Sirera R,. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006; 51: 143-158. (Pubitemid 43144358)
26. Hicklin DJ, Ellis LM,. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23: 1011-1027. (Pubitemid 46202320)
27. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer. 2000; 89: 475-483.
28. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol. 2001; 19: 432-441. (Pubitemid 32112856)
29. Matsuyama M, Chijiwa T, Inoue Y, et al. Alternative splicing variant of vascular endothelial growth factor-A is a critical prognostic factor in non-small cell lung cancer. Oncol Rep. 2009; 22: 1407-1413.
30. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E,. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004; 46: 293-298. (Pubitemid 39487303)
31. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH,. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res. 2008; 14: 1407-1412. (Pubitemid 351413922)
32. Zhang W, Dahlberg SE, Yand D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599 [abstract]. J Clin Oncol. 2009; 27. Abstract 8032.
33. Zhang W, Lee J, Schiller JH, Carbone DP, Chung CH, Lenz H,. Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501 [abstract]. J Clin Oncol. 2010; 28. Abstract 7607.
34. Hanrahan EO, Ryan AJ, Mann H, et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res. 2009; 15: 3600-3609.
35. Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009; 14: 378-390.
36. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advance non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC) [abstract]. J Clin Oncol. 2009; 27: 807s. Abstract CRA8003.
37. De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL) [abstract]. J Clin Oncol. 2009; 27: Abstract 8010.
38. Natale RB, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least 1 prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST) [abstract]. J Clin Oncol. 2009; 27: 409s. Abstract 8009.
39. Lee J, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2010; 28: 7525.
40. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010; 28: 193-201.
41. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006; 24: 25-35. (Pubitemid 46630490)
42. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16-24. (Pubitemid 46630489)
43. Ellis LM, Hicklin DJ,. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8: 579-591.
44. van Iterson V, Leidenius M, von Smitten K, Bono P, Heikkila P,. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am J Clin Pathol. 2007; 128: 759-766. (Pubitemid 350133986)
45. Goldman J, Rutkowski JM, Shields JD, et al. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J. 2007; 21: 1003-1012. (Pubitemid 46495690)
46. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y,. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 2003; 97: 457-464. (Pubitemid 36133813)
47. Donnem T, Al-Saad S, Al-Shibli K, et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res. 2007; 13: 6649-6657. (Pubitemid 350206800)
48. Andersen S, Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM,. Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy. J Thorac Oncol. 2009; 4: 463-471.
49. Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 2006; 53: 91-96. (Pubitemid 43831360)
50. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its 2 receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol. 1999; 188: 369-377. (Pubitemid 29327434)
51. Bonnesen B, Pappot H, Holmstav J, Skov BG,. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer. 2009; 66: 314-318.
52. Chen F, Takenaka K, Ogawa E, et al. Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer. Clin Cancer Res. 2004; 10: 8548-8553. (Pubitemid 40053423)
53. Takenaka K, Katakura H, Chen F, et al. The ratio of membrane-bound form Flt-1 mRNA to VEGF mRNA correlates with tumor angiogenesis and prognosis in non-small cell lung cancer. Cancer Lett. 2007; 246: 34-40. (Pubitemid 44959371)
54. Kim ES, Herbst RS, Lee JJ, et al. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer. Presented at the 101st Annual Meeting of the American Association for Cancer Research, April 17-21, 2010, Washington, DC.
55. Azim HA, Jr, Ganti AK,. Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand? Cancer Treat Rev. 2006; 32: 630-636. (Pubitemid 44645025)
56. Herbst RS, Blumenschein GR Jr, Kim ES, et al. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial [abstract]. J Clin Oncol (Meeting Abstracts). 2010; 28: 7609.
57. Alvarez RH, Kantarjian HM, Cortes JE,. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc. 2006; 81: 1241-1257. (Pubitemid 44316290)
58. Bergsten E, Uutela M, Li X, et al. PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor. Nat Cell Biol. 2001; 3: 512-516. (Pubitemid 32422089)
59. Andrae J, Gallini R, Betsholtz C,. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22: 1276-1312. (Pubitemid 351717519)
60. Abramsson A, Lindblom P, Betsholtz C,. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest. 2003; 112: 1142-1151. (Pubitemid 38056291)
61. Jain RK, Booth MF,. What brings pericytes to tumor vessels? J Clin Invest. 2003; 112: 1134-1136. (Pubitemid 38056288)
62. Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009; 15: 21-34.
63. Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 2008; 112: 2119-2129. (Pubitemid 351628620)
64. Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F,. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1719-1722.
65. Nakamura Y, Tanaka F, Yoshikawa Y, et al. PDGF-BB is a novel prognostic factor in colorectal cancer. Ann Surg Oncol. 2008; 15: 2129-2136.
66. Korc M, Friesel RE,. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009; 9: 639-651.
67. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998; 141: 1659-1673. (Pubitemid 28309179)
68. Beenken A, Mohammadi M,. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8: 235-253.
69. Casanovas O, Hicklin DJ, Bergers G, Hanahan D,. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8: 299-309. (Pubitemid 41443415)
70. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M,. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005; 16: 159-178. (Pubitemid 40616114)
71. Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM,. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol. 2009; 4: 578-585.
72. Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T,. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg. 2004; 25: 443-448. (Pubitemid 38340585)
73. Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW,. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer. 2009; 65: 371-376.
74. Fish JE, Srivastava D,. MicroRNAs: opening a new vein in angiogenesis research. Sci Signal. 2009; 2:p e1.
75. Ortholan C, Puissegur MP, Ilie M, Barbry P, Mari B, Hofman P,. MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets. Curr Med Chem. 2009; 16: 1047-1061.
76. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S,. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 2010; 70: 36-45.
77. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9: 189-198. (Pubitemid 43357945)
78. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008; 13: 48-57.
79. Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009; 69: 5776-5783.
80. Murugaiyan G, Saha B,. Protumor vs antitumor functions of IL-17. J Immunol. 2009; 183: 4169-4175.
81. Waugh DJ, Wilson C,. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14: 6735-6741.
82. Yuan A, Chen JJW, Yao PL, Yang PC,. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci. 2005; 10: 853-865.
83. Orditura M, De Vita F, Catalano G, et al. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res. 2002; 22: 1129-1135. (Pubitemid 36051185)
84. Yuan A, Yang P-C, Yu C-J, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 2000; 162: 1957-1963.
85. Chen X, Wan J, Liu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2009; 69: 348-354.
86. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J,. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995; 87: 581-586.
87. Nikolinakos PG, Altorki N, Yankelevitz D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res. 2010; 70: 2171-2179.
88. Krysan K, Reckamp KL, Sharma S, Dubinett SM,. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem. 2006; 6: 209-220. (Pubitemid 43796639)
89. Wheeler-Jones CP, Farrar C, Garonna E,. Protease-activated receptors, cyclo-oxygenases and pro-angiogenic signalling in endothelial cells. Biochem Soc Trans. 2009; 37 (pt 6): 1179-1183.
90. Tsubochi H, Sato N, Hiyama M, et al. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Ann Thorac Surg. 2006; 82: 1198-1204. (Pubitemid 44402329)
91. Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer. 2005; 115: 545-555. (Pubitemid 40656711)
92. Timotheadou E, Skarlos DV, Samantas E, et al. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Res. 2007; 27: 4481-4489.
93. Nakashima T, Huang C, Liu D, et al. Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Br J Cancer. 2003; 88: 1727-1733. (Pubitemid 36760417)
94. Gogali A, Charalabopoulos K, Zampira I, et al. Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest. 2010; 138: 1173-1179.
95. Guney N, Soydinc HO, Derin D, et al. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer. Med Oncol. 2008; 25: 194-200.
96. Chang H, Iizasa T, Shibuya K, et al. Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma. Cancer. 2004; 100: 1665-1672. (Pubitemid 38456344)
97. Iizasa T, Chang H, Suzuki M, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res. 2004; 10: 5361-5366. (Pubitemid 39100472)
98. Yoo J, Jung JH, Lee MA, et al. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci. 2007; 22: 318-325.
99. West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L,. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol. 2009; 4: S1029-S1039.
100. Bernaards C, Hegde P, Chen D, et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: analysis of phase III studies [abstract]. J Clin Oncol. 2010; 28. Abstract 10519.